Ignite Creation Date:
2024-05-06 @ 3:51 AM
Last Modification Date:
2024-10-26 @ 11:40 AM
Study NCT ID:
NCT02394886
Status:
COMPLETED
Last Update Posted:
2015-10-16
First Post:
2015-03-03
Brief Title:
Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers
Sponsor:
Anterogen Co Ltd
Organization:
Anterogen Co Ltd
Study Overview
Official Title:
A Phase I Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase I open-label study to evaluate the safety of ALLO-ASC-DFU in diabetic foot ulcers patients ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor VEGF and hepatocyte growth factor HGF which can enhance wound healing and regeneration of new tissue finally may provide an new option in treating a diabetic foot ulcer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None